Boxer Capital
Latest statistics and disclosures from Boxer Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRTX, CYTK, SWTX, RVMD, APLS, and represent 35.60% of Boxer Capital's stock portfolio.
- Added to shares of these 10 stocks: ARGX (+$29M), ARVN (+$25M), GPCR (+$16M), TNGX (+$11M), IMVT (+$11M), NKTX (+$9.5M), SYRE (+$5.4M), SRPT, THRD, PRTA.
- Started 4 new stock positions in GPCR, ARVN, NKTX, SYRE.
- Reduced shares in these 10 stocks: AMLX (-$38M), , VTYX (-$30M), , , SAGE (-$23M), VKTX (-$22M), PMVP (-$19M), IOVA (-$19M), Point Biopharma Global (-$17M).
- Sold out of its positions in ABOS, FOLD, AMLX, ASND, CNTA, COGT, CGEM, Eqrx, EXEL, GOSS.
- Boxer Capital was a net seller of stock by $-242M.
- Boxer Capital has $2.0B in assets under management (AUM), dropping by 6.81%.
- Central Index Key (CIK): 0001465837
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Boxer Capital
Boxer Capital holds 52 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Mirati Therapeutics (MRTX) | 9.4 | $188M | 3.2M | 58.75 |
|
|
Cytokinetics Com New (CYTK) | 8.7 | $175M | 2.1M | 83.49 |
|
|
Springworks Therapeutics (SWTX) | 6.2 | $125M | 3.4M | 36.50 |
|
|
Revolution Medicines (RVMD) | 6.1 | $123M | -8% | 4.3M | 28.68 |
|
Apellis Pharmaceuticals (APLS) | 5.1 | $103M | 1.7M | 59.86 |
|
|
BeiGene Sponsored Adr (BGNE) | 4.5 | $90M | 500k | 180.36 |
|
|
Tyra Biosciences (TYRA) | 4.5 | $89M | 6.4M | 13.85 |
|
|
ImmunoGen (IMGN) | 4.4 | $88M | 3.0M | 29.65 |
|
|
Nuvalent Inc-a (NUVL) | 4.1 | $82M | -7% | 1.1M | 73.59 |
|
Tango Therapeutics (TNGX) | 4.0 | $81M | +15% | 8.2M | 9.90 |
|
Karuna Therapeutics Ord (KRTX) | 3.9 | $79M | 250k | 316.51 |
|
|
Ideaya Biosciences (IDYA) | 3.9 | $78M | 2.2M | 35.58 |
|
|
Sarepta Therapeutics (SRPT) | 3.1 | $63M | +8% | 650k | 96.43 |
|
Argenx SE Sponsored Adr (ARGX) | 3.0 | $61M | +88% | 160k | 380.43 |
|
Merus N V (MRUS) | 2.6 | $52M | 1.9M | 27.50 |
|
|
Rocket Pharmaceuticals (RCKT) | 2.2 | $44M | 1.5M | 29.97 |
|
|
Immunovant (IMVT) | 2.1 | $42M | +33% | 1.0M | 42.13 |
|
Akero Therapeutics (AKRO) | 2.0 | $39M | 1.7M | 23.35 |
|
|
Legend Biotech Corp Sponsored Ads (LEGN) | 1.8 | $36M | 600k | 60.17 |
|
|
Axsome Therapeutics (AXSM) | 1.6 | $32M | 400k | 79.59 |
|
|
Arcus Biosciences Incorporated (RCUS) | 1.5 | $31M | 1.6M | 19.10 |
|
|
Anaptysbio Inc Common (ANAB) | 1.4 | $28M | 1.3M | 21.42 |
|
|
Xenon Pharmaceuticals (XENE) | 1.4 | $28M | 600k | 46.06 |
|
|
Arvinas Ord (ARVN) | 1.2 | $25M | NEW | 609k | 41.16 |
|
Prothena Corp SHS (PRTA) | 1.2 | $24M | +6% | 665k | 36.34 |
|
Kalvista Pharmaceuticals (KALV) | 1.0 | $20M | 1.7M | 12.25 |
|
|
Relay Therapeutics (RLAY) | 1.0 | $20M | 1.8M | 11.01 |
|
|
Iteos Therapeutics (ITOS) | 1.0 | $20M | 1.8M | 10.95 |
|
|
Day One Biopharmaceuticals I (DAWN) | 0.9 | $17M | 1.2M | 14.60 |
|
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $16M | NEW | 400k | 40.76 |
|
Oric Pharmaceuticals (ORIC) | 0.8 | $16M | 1.7M | 9.20 |
|
|
Iovance Biotherapeutics (IOVA) | 0.6 | $11M | -62% | 1.4M | 8.13 |
|
Prelude Therapeutics (PRLD) | 0.5 | $11M | +2% | 2.6M | 4.27 |
|
Avidity Biosciences Ord (RNA) | 0.5 | $10M | 1.1M | 9.05 |
|
|
Nkarta (NKTX) | 0.5 | $9.5M | NEW | 1.4M | 6.60 |
|
Enliven Therapeutics (ELVN) | 0.4 | $8.9M | 646k | 13.84 |
|
|
Third Harmonic Bio (THRD) | 0.4 | $8.2M | +44% | 750k | 10.97 |
|
Zentalis Pharmaceuticals (ZNTL) | 0.3 | $6.8M | 450k | 15.15 |
|
|
Geron Corporation (GERN) | 0.3 | $6.3M | 3.0M | 2.11 |
|
|
Spyre Therapeutics Com New (SYRE) | 0.3 | $5.4M | NEW | 250k | 21.52 |
|
Health Sciences Acq Corp 2 (OBIO) | 0.1 | $2.2M | 238k | 9.13 |
|
|
Fate Therapeutics (FATE) | 0.1 | $1.9M | 500k | 3.74 |
|
|
Kodiak Sciences (KOD) | 0.1 | $1.8M | 600k | 3.04 |
|
|
Bioatla (BCAB) | 0.1 | $1.7M | 686k | 2.46 |
|
|
Black Diamond Therapeutics (BDTX) | 0.1 | $1.4M | 506k | 2.81 |
|
|
Rain Therapeutics (RAIN) | 0.1 | $1.4M | 1.2M | 1.20 |
|
|
Milestone Pharmaceuticals (MIST) | 0.0 | $516k | 309k | 1.67 |
|
|
DBV Technologies S A Sponsored Adr (DBVT) | 0.0 | $476k | -49% | 500k | 0.95 |
|
Protara Therapeutics Com Stk (TARA) | 0.0 | $392k | 209k | 1.88 |
|
|
Atreca Cl A Com (BCEL) | 0.0 | $291k | 2.2M | 0.13 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $16k | 267k | 0.06 |
|
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.3k | 67k | 0.02 |
|
Past Filings by Boxer Capital
SEC 13F filings are viewable for Boxer Capital going back to 2015
- Boxer Capital 2023 Q4 filed Feb. 14, 2024
- Boxer Capital 2023 Q3 filed Nov. 14, 2023
- Boxer Capital 2023 Q2 filed Aug. 14, 2023
- Boxer Capital 2023 Q1 filed May 15, 2023
- Boxer Capital 2022 Q4 filed Feb. 14, 2023
- Boxer Capital 2022 Q3 filed Nov. 14, 2022
- Boxer Capital 2022 Q2 filed Aug. 15, 2022
- Boxer Capital 2022 Q1 filed May 16, 2022
- Boxer Capital 2021 Q4 filed Feb. 14, 2022
- Boxer Capital 2021 Q3 filed Nov. 15, 2021
- Boxer Capital 2021 Q2 filed Aug. 16, 2021
- Boxer Capital 2021 Q1 filed May 17, 2021
- Boxer Capital 2020 Q4 filed Feb. 16, 2021
- Boxer Capital 2020 Q3 restated filed Nov. 17, 2020
- Boxer Capital 2020 Q3 filed Nov. 16, 2020
- Boxer Capital 2020 Q2 filed Aug. 14, 2020